Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NewAmsterdam Pharma Company ( (NAMS) ) has issued an announcement.
On April 20, 2026, NewAmsterdam Pharma Company N.V. and Chief Accounting Officer Louise Kooij agreed that her employment would end effective August 31, 2026, and on April 24, 2026, they executed a separation agreement detailing her departure terms. Under the agreement, Kooij will receive a lump sum equal to 12 months of base salary, a pro-rated 2026 bonus at target achievement through the separation date, payment for accrued but unused vacation in line with Dutch law, extended vesting of her outstanding equity awards through January 10, 2027, and an option exercise window until February 10, 2027, in exchange for standard restrictive covenants and a release of claims, signaling an orderly transition in the company’s senior finance leadership.
The separation terms for NewAmsterdam’s Chief Accounting Officer include a year of salary, pro-rated bonus, and equity vesting extensions. These arrangements indicate a structured and negotiated leadership transition in the company’s finance function with protections for both parties.
The agreement extends vesting on Kooij’s stock options and RSUs into early 2027 while setting a clear end date for option exercise. This underscores NewAmsterdam’s effort to manage executive turnover smoothly without immediate disruption to its financial governance framework.
The most recent analyst rating on (NAMS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
The score is anchored by solid financial stability from a low-debt balance sheet, but held back by persistent losses and ongoing cash burn. Technicals are mixed with near-term weakness, while valuation is penalized by negative earnings and no dividend support. Positive recent corporate updates provide some offset via clinical/regulatory progress and funding runway.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V. is a biopharmaceutical company focused on developing and commercializing innovative therapies, operating within the global pharmaceutical and life sciences industry. The company’s activities center on advancing drug candidates through clinical development and regulatory pathways to address unmet medical needs in its target patient populations.
Average Trading Volume: 810,246
Technical Sentiment Signal: Buy
Current Market Cap: $3.68B
Find detailed analytics on NAMS stock on TipRanks’ Stock Analysis page.